Stock OCUP OCUPHIRE PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
1.64 USD +3.47% Intraday chart for Ocuphire Pharma, Inc. +7.19% -45.51%
Apr. 11 Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment MT
Apr. 11 Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc CI

Evolution of the average Target Price on Ocuphire Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

86b4fa24a54479.ra8YTAhmQdixyaiUO8ggf0wtoBVEyn1-GXCx6MUxCso.5ctiPGkBE7TU8MeiArANBzl52V4LvBJGfj78mZVBfZP69lAbeAgAgNOMzw~a9fd262ab40eef0c83925e62112811f0

Analyst Recommendations on Ocuphire Pharma, Inc.

Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating MT
Cantor Fitzgerald Cuts Ocuphire Pharma's Price Target to $17 From $24, Maintains Overweight Rating MT
HC Wainwright Adjusts Ocuphire Pharma's Price Target to $20 From $26, Keeps Buy Rating MT
History shows stocks can weather rate hike cycle RE
HC Wainwright Starts Ocuphire Pharma at Buy With $26 Price Target MT
OCUPHIRE PHARMA : Alliance Global Securities Initiates Coverage on Ocuphire Pharma With Buy Rating, $25 Price Target MT
OCUPHIRE PHARMA : JonesTrading Starts Ocuphire Pharma at Buy With $20 Price Target MT
OCUPHIRE PHARMA : Cantor Fitzgerald Adjusts Ocuphire Pharma PT to $20 From $15, Maintains Overweight Rating MT
OCUPHIRE PHARMA : Canaccord Starts Ocuphire Pharma at Buy with $22 Price Target MT
OCUPHIRE PHARMA : Cantor Fitzgerald Initiates Ocuphire Pharma at Overweight With $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.64 USD
Average target price
19.5 USD
Spread / Average Target
+1,089.02%
High Price Target
22 USD
Spread / Highest target
+1,241.46%
Low Price Target
16 USD
Spread / Lowest Target
+875.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ocuphire Pharma, Inc.

Alliance Global Partners
Cantor Fitzgerald
HC Wainwright
JonesTrading Institutional Services
Canaccord Genuity

Ratings for Ocuphire Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. OCUP Stock
  4. Consensus Ocuphire Pharma, Inc.